Kezar Life Sciences, Inc. - KZR STOCK NEWS

Kezar Life Sciences announced the granting of nonqualified stock options for 29,000 shares to two employees, with an exercise price of $12.54 per share, corresponding to its closing price on May 2, 2022. These options will vest over four years, starting with 25% after one year and the remainder vesting monthly. This move follows Nasdaq Listing Rule 5635(c)(4) and is part of Kezar's strategy to attract talent while continuing to develop therapies for immune-mediated and oncologic disorders.

Kezar Life Sciences announced topline results from the PRESIDIO Phase 2 trial of zetomipzomib (KZR-616) in patients with dermatomyositis and polymyositis. While most patients showed improvements in the Total Improvement Score, there was no significant differentiation from the placebo group. The drug demonstrated a favorable safety profile, with mild-to-moderate adverse events. Cash reserves stand at approximately $253 million as of April 30, 2022. Results from the ongoing MISSION Phase 2 trial in lupus nephritis are expected in June 2022, maintaining optimism for the drug’s potential.

Kezar Life Sciences, Inc. (NASDAQ: KZR) has granted a nonqualified stock option to an employee for 100,000 shares at an exercise price of $15.44, aligning with the stock's closing price on April 13, 2022. This option is part of an inducement award critical to the individual’s employment and will vest over four years, with 25% vesting on the first anniversary, followed by monthly vesting. Kezar specializes in developing innovative treatments for immune-mediated and oncologic disorders, focusing on first-in-class therapies like Zetomipzomib and KZR-261.

Kezar Life Sciences reported strong progress in 2021, achieving target enrollment for Phase 2 trials of KZR-616, now named zetomipzomib. The company has $208.4 million in cash and equivalents as of December 31, 2021, up from $140.4 million in 2020. Although net loss widened to $54.6 million for the year, R&D expenses increased significantly due to advancements in clinical programs. Topline data from the MISSION and PRESIDIO trials is expected in Q2 2022, and a new Phase 1 trial for KZR-261 has been initiated, indicating ongoing development momentum.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology firm focused on immune-mediated and oncologic disorders, will have its Chief Medical Officer, Noreen Roth Henig, participate in the Kidney Disease/Fibrosis Panel at the Cowen 42nd Annual Health Care Conference. The event is scheduled for Wednesday, March 9, 2022, at 2:10 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Kezar is developing innovative therapies such as KZR-616 for various chronic diseases and KZR-261 for cancer treatment.

Kezar Life Sciences announced the appointment of Courtney Wallace to its Board of Directors. This strategic move is timed with the company's ongoing evolution and aims to enhance its business development efforts. Wallace brings over a decade of experience in healthcare, previously serving as Chief Business Officer at Beam Therapeutics and in various roles at Celgene Corporation. Kezar is focused on developing innovative treatments for immune-mediated and oncologic disorders, with its lead asset KZR-616 currently in Phase 2 clinical trials.

Kezar Life Sciences reported interim results from the Phase 2 MISSION clinical trial of KZR-616, a selective immunoproteasome inhibitor, in patients with lupus nephritis. Key outcomes include:

• 4 out of 5 patients achieved partial or complete renal response
• Safety profile appeared favorable with no new safety signals
• Encouraging proteinuria reduction observed at both 13 and 25 weeks

Top-line data is expected in Q2 2022, highlighting KZR-616's potential in treating this challenging condition.

Kezar Life Sciences (Nasdaq: KZR) announced its participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing from November 18 at 3:00 a.m. EST. The webcast can be accessed through the Events & Presentations section on Kezar's website, with an archived replay available for 90 days post-conference. The company focuses on developing treatments for immune-mediated and oncologic disorders, with KZR-616 in Phase 2 trials and KZR-261 in Phase 1 trials.

Kezar Life Sciences has closed a $50 million senior secured term loan with Oxford Finance LLC. The funds will be utilized for general growth capital and to advance clinical candidates KZR-616 and KZR-261. The financing aims to strengthen Kezar's balance sheet and support the ongoing development of its innovative therapies targeting immune-mediated and oncologic disorders. The company anticipates top-line data readouts for KZR-616 in Q2 2022, enhancing its prospects in the competitive biopharmaceutical landscape.